TC
PLRX icon

TwinBeech Capital’s Pliant Therapeutics PLRX Stock Holding History

TwinBeech Capital’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-81,422
Closed -$2.17M – 801
2023
Q1 		$2.17M Buy
+81,422
New +$2.32M 0.04% 361

Other funds holding PLRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

TwinBeech Capital's PLRX Position: Q2 2023 in Review

TwinBeech Capital sold out of Pliant Therapeutics (PLRX) in Q2 2023, closing a stake of 81,422 shares — an estimated $2.17M sold.

TwinBeech Capital first reported a position in PLRX in Q1 2023 and held it in 1 quarter. The position peaked at $2.17M in Q1 2023. 144 funds tracked by Wall St. Rank hold PLRX as of Q2 2023.

  • TwinBeech Capital reported no remaining Pliant Therapeutics position as of Q2 2023 after selling out during the quarter.
  • TwinBeech Capital sold 81,422 Pliant Therapeutics shares in Q2 2023, an estimated $2.17M.
  • TwinBeech Capital first reported a position in Pliant Therapeutics in Q1 2023 and held it in 1 quarter.
  • TwinBeech Capital's Pliant Therapeutics position peaked at $2.17M in Q1 2023.
  • 144 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2023.

Based on TwinBeech Capital's 13F filing for Q2 2023, filed 14 Aug 2023.